Loading
A phase 1/2 trial of cetuximab, cemiplimab and adagrasib in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations is a phase 1/2, interventional study registered as NCT06412198 by M.D. Anderson Cancer Center, with a registry enrolment figure of 31 participants, started 2024-08-28 and due to reach its primary completion in 2029-03-01. Interventions recorded: Cetuximab; Cemiplimab; Adagrasib. Conditions listed: Metastatic Colorectal Cancer; KRAS G12C Mutations. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of advanced/metastatic microsatellite stable colorectal cancer with KRASG12C mutation with 1+ prior line(s) of therapy". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cemiplimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors, Cetuximab, Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/